Functional, Morphological And Safety Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration - 3 Years Of Follow-up

NCT01027468 NA COMPLETED Results posted

200 eyes with each subtype of neovascular age-related macular degeneration will be included in this study and 3 years after the initial intravitreal bevacizumab, best-corrected visual acuity (BCVA) will be measured using Snellen charts at 6m. Central retinal thickness (CRT) will be measured using Stratus OCT and Cirrus SD-OCT (Zeiss). Data of treatment-naive eyes (group 1) were compared to the data of eyes that had undergone prior treatment with photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide (group 2).

Details

Lead sponsor	Medical University of Vienna
Phase	NA
Status	COMPLETED
Enrolment	160
Start date	2009-08
Completion	2009-12

Conditions

• Neovascular Age-related Macular Degeneration

Interventions

• Bevacizumab

Primary outcomes

• Vision — 3 years after first intravitreal bevacizumab treatment
  Best-corrected visual acuity converted to logMAR (MAR=minimum angle of resolution) for statistical analysis
• CRT (Central Retinal Thickness) — 3 years after initial intravitreal bevacizumab treatment
  Central retinal thickness measured in µm